Efficacy News and Research

RSS
FDA approves Tenaxis Medical’s ArterX Surgical Sealant

FDA approves Tenaxis Medical’s ArterX Surgical Sealant

4 Mar 2013
Médecins Sans Frontières’ concerns over TPP negotiations

Médecins Sans Frontières’ concerns over TPP negotiations

4 Mar 2013
PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

4 Mar 2013
DBV Technologies total revenues increase to €2,776,588 for full year 2012

DBV Technologies total revenues increase to €2,776,588 for full year 2012

4 Mar 2013
Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

Regeneron, Sanofi announce pooled data from Phase 1b trials with dupilumab for atopic dermatitis

4 Mar 2013
Melanoma tumours deliberately create conditions that knock out body's premier immune defence

Melanoma tumours deliberately create conditions that knock out body's premier immune defence

2 Mar 2013
New data from KYTHERA Biopharmaceuticals’ ATX-101 studies on double chin

New data from KYTHERA Biopharmaceuticals’ ATX-101 studies on double chin

2 Mar 2013
Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

Pivotal study of olesoxime in Spinal Muscular Atrophy receives positive interim review

1 Mar 2013
Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

Urea cycle disorder patient successfully treated by Promethera(R) HepaStem in Phase I/II trial in France

1 Mar 2013
Scientists take important step toward designing a uniform protocol for microbiome research

Scientists take important step toward designing a uniform protocol for microbiome research

1 Mar 2013
Oraya Therapy safe and effective for patients with wet AMD

Oraya Therapy safe and effective for patients with wet AMD

1 Mar 2013
Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

1 Mar 2013
Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

Positive results from Anacor’s second of two Phase 3 trials of tavaborole for onychomycosis

28 Feb 2013
TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

28 Feb 2013
Telehealth enthusiasm dampened

Telehealth enthusiasm dampened

28 Feb 2013
EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept fourth quarter revenue decreases to $0.1 million

28 Feb 2013
Long-term treatment with spironolactone improves left ventricular diastolic function in HF patients

Long-term treatment with spironolactone improves left ventricular diastolic function in HF patients

28 Feb 2013
Freie Universität Berlin research team examines thermoresponsive nanogels for treatment of cancer

Freie Universität Berlin research team examines thermoresponsive nanogels for treatment of cancer

27 Feb 2013
Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

27 Feb 2013
FDA's Oncologic Drugs Advisory Committee to review NDA for tivozanib

FDA's Oncologic Drugs Advisory Committee to review NDA for tivozanib

27 Feb 2013

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback